IBDEI1F2 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22912,0)
 ;;=L43.2^^76^987^16
 ;;^UTILITY(U,$J,358.3,22912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22912,1,3,0)
 ;;=3^Lichenoid Drug Reaction
 ;;^UTILITY(U,$J,358.3,22912,1,4,0)
 ;;=4^L43.2
 ;;^UTILITY(U,$J,358.3,22912,2)
 ;;=^5009180
 ;;^UTILITY(U,$J,358.3,22913,0)
 ;;=L43.9^^76^987^13
 ;;^UTILITY(U,$J,358.3,22913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22913,1,3,0)
 ;;=3^Lichen Planus,Unspec
 ;;^UTILITY(U,$J,358.3,22913,1,4,0)
 ;;=4^L43.9
 ;;^UTILITY(U,$J,358.3,22913,2)
 ;;=^5009183
 ;;^UTILITY(U,$J,358.3,22914,0)
 ;;=L93.0^^76^987^18
 ;;^UTILITY(U,$J,358.3,22914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22914,1,3,0)
 ;;=3^Lupus,Erythematosus,Discoid
 ;;^UTILITY(U,$J,358.3,22914,1,4,0)
 ;;=4^L93.0
 ;;^UTILITY(U,$J,358.3,22914,2)
 ;;=^5009467
 ;;^UTILITY(U,$J,358.3,22915,0)
 ;;=L93.2^^76^987^20
 ;;^UTILITY(U,$J,358.3,22915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22915,1,3,0)
 ;;=3^Lupus,Erythematosus,Local
 ;;^UTILITY(U,$J,358.3,22915,1,4,0)
 ;;=4^L93.2
 ;;^UTILITY(U,$J,358.3,22915,2)
 ;;=^5009469
 ;;^UTILITY(U,$J,358.3,22916,0)
 ;;=L93.1^^76^987^21
 ;;^UTILITY(U,$J,358.3,22916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22916,1,3,0)
 ;;=3^Lupus,Erythematosus,Subacute Cutaneous
 ;;^UTILITY(U,$J,358.3,22916,1,4,0)
 ;;=4^L93.1
 ;;^UTILITY(U,$J,358.3,22916,2)
 ;;=^5009468
 ;;^UTILITY(U,$J,358.3,22917,0)
 ;;=M32.0^^76^987^19
 ;;^UTILITY(U,$J,358.3,22917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22917,1,3,0)
 ;;=3^Lupus,Erythematosus,Drug-Induced Systemic
 ;;^UTILITY(U,$J,358.3,22917,1,4,0)
 ;;=4^M32.0
 ;;^UTILITY(U,$J,358.3,22917,2)
 ;;=^5011752
 ;;^UTILITY(U,$J,358.3,22918,0)
 ;;=M32.10^^76^987^22
 ;;^UTILITY(U,$J,358.3,22918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22918,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic
 ;;^UTILITY(U,$J,358.3,22918,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,22918,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,22919,0)
 ;;=M32.19^^76^987^24
 ;;^UTILITY(U,$J,358.3,22919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22919,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic,Skin Involvmnt
 ;;^UTILITY(U,$J,358.3,22919,1,4,0)
 ;;=4^M32.19
 ;;^UTILITY(U,$J,358.3,22919,2)
 ;;=^5011759
 ;;^UTILITY(U,$J,358.3,22920,0)
 ;;=M32.9^^76^987^23
 ;;^UTILITY(U,$J,358.3,22920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22920,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic w/o Organ Involvmnt
 ;;^UTILITY(U,$J,358.3,22920,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,22920,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,22921,0)
 ;;=E88.1^^76^987^17
 ;;^UTILITY(U,$J,358.3,22921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22921,1,3,0)
 ;;=3^Lipodystrophy NOS
 ;;^UTILITY(U,$J,358.3,22921,1,4,0)
 ;;=4^E88.1
 ;;^UTILITY(U,$J,358.3,22921,2)
 ;;=^5003028
 ;;^UTILITY(U,$J,358.3,22922,0)
 ;;=C85.19^^76^987^2
 ;;^UTILITY(U,$J,358.3,22922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22922,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22922,1,4,0)
 ;;=4^C85.19
 ;;^UTILITY(U,$J,358.3,22922,2)
 ;;=^5001710
 ;;^UTILITY(U,$J,358.3,22923,0)
 ;;=C85.13^^76^987^5
 ;;^UTILITY(U,$J,358.3,22923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22923,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Intra-Abdominal Lymph Nodes
 ;;^UTILITY(U,$J,358.3,22923,1,4,0)
 ;;=4^C85.13
 ;;^UTILITY(U,$J,358.3,22923,2)
 ;;=^5001704
 ;;^UTILITY(U,$J,358.3,22924,0)
 ;;=C85.16^^76^987^6
 ;;^UTILITY(U,$J,358.3,22924,1,0)
 ;;=^358.31IA^4^2
